lncRNAs dysregulation in monocytes from primary antiphospholipid syndrome patients: a bioinformatic and an experimental proof-of-concept approach

Carlos A. Guzmán-Martín, Yaneli Juárez-Vicuña, Aarón Domínguez-López, Javier González-Ramírez, Luis M. Amezcua-Guerra, Laura A. Martínez-Martínez, Fausto Sánchez-Muñoz

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

4 Citas (Scopus)

Resumen

Background: Antiphospholipid syndrome (APS) is the main cause of acquired thrombophilia where peripheral circulating cells such as monocytes have a key role. Currently, several studies have linked long non-coding RNAs (lncRNAs) in different inflammatory and autoimmune processes, including lupus. However, the role of lncRNAs in antiphospholipid syndrome is unknown, therefore, we aimed to select and measure expression levels of three lncRNAs based on its abundance in monocytes from APS patients. Methods: Selection of lncRNAs candidates were carried out based on its abundance in monocytes and their relationship with Perez-Sanchez miRNA signature by using miRNet 2.0 bioinformatic tool, then lncRNAs expression levels was measured in monocytes by RT-qPCR. Results: This is the first study to report that lncRNAs: FGD5-AS1, OIP5-AS1 and GAS5 are promising candidates for play a role on APS monocytes and they are expressed differently between patients and controls. Conclusions: OIP5-AS1, FGD5-AS1 and GAS5 are downregulated on monocytes from APS patients.

Idioma originalInglés
Páginas (desde-hasta)937-941
Número de páginas5
PublicaciónMolecular Biology Reports
Volumen50
N.º1
DOI
EstadoPublicada - ene. 2023

Huella

Profundice en los temas de investigación de 'lncRNAs dysregulation in monocytes from primary antiphospholipid syndrome patients: a bioinformatic and an experimental proof-of-concept approach'. En conjunto forman una huella única.

Citar esto